Profiles of myeloma patients in this study
| Patient* . | Age (y) . | Sex . | Disease duration after diagnosis (mo) . | Disease stage† . | M-component type‡ . | Chemotherapy treatment within 6 mo of study entry . | Duration since last SCT (mo)1-153 . |
|---|---|---|---|---|---|---|---|
| A | 70 | M | 109 | IA | IgG-κ | No | — |
| B | 53 | F | 61 | IIA | IgG-κ | No | 27 |
| C | 82 | F | 47 | IIIB | IgG-κ | Yes | — |
| D | 82 | F | 71 | IIIA | IgG-λ | Yes | — |
| E | 37 | M | 67 | IIA | IgG-κ | No | 59 |
| F | 74 | M | 81 | IIIB | IgG-κ | Yes | — |
| G | 71 | F | 46 | IIB | IgG-κ | No | — |
| H | 60 | M | 17 | IIB | IgG-λ | Yes1-155 | — |
| I | 44 | F | 99 | IIIA | κ-LC | No | 46 |
| J | 86 | M | 37 | IA | IgG-λ | No | — |
| K | 74 | M | 145 | IA | IgG-λ | No | — |
| L | 43 | M | 4 | IIA | IgG-λ | Yes | — |
| M | 55 | F | 2 | IIA | IgG-κ | Yes | — |
| N | 56 | F | 35 | IIA | IgG-κ | No | — |
| O | 72 | M | 27 | IIIA | IgG-κ | Yes1-155 | 60 |
| P | 61 | M | 61 | IIA | IgA-κ | No | — |
| Patient* . | Age (y) . | Sex . | Disease duration after diagnosis (mo) . | Disease stage† . | M-component type‡ . | Chemotherapy treatment within 6 mo of study entry . | Duration since last SCT (mo)1-153 . |
|---|---|---|---|---|---|---|---|
| A | 70 | M | 109 | IA | IgG-κ | No | — |
| B | 53 | F | 61 | IIA | IgG-κ | No | 27 |
| C | 82 | F | 47 | IIIB | IgG-κ | Yes | — |
| D | 82 | F | 71 | IIIA | IgG-λ | Yes | — |
| E | 37 | M | 67 | IIA | IgG-κ | No | 59 |
| F | 74 | M | 81 | IIIB | IgG-κ | Yes | — |
| G | 71 | F | 46 | IIB | IgG-κ | No | — |
| H | 60 | M | 17 | IIB | IgG-λ | Yes1-155 | — |
| I | 44 | F | 99 | IIIA | κ-LC | No | 46 |
| J | 86 | M | 37 | IA | IgG-λ | No | — |
| K | 74 | M | 145 | IA | IgG-λ | No | — |
| L | 43 | M | 4 | IIA | IgG-λ | Yes | — |
| M | 55 | F | 2 | IIA | IgG-κ | Yes | — |
| N | 56 | F | 35 | IIA | IgG-κ | No | — |
| O | 72 | M | 27 | IIIA | IgG-κ | Yes1-155 | 60 |
| P | 61 | M | 61 | IIA | IgA-κ | No | — |
M indicates myeloma; SCT, stem-cell transplantation; Ig, immunoglobulin; LC, light chain.
CDR3 length analysis and sequencing were performed on specimens of patients A through F. Propidium iodide–labeling analysis was conducted on specimens of all multiple myeloma patients except G through I. CD95 analysis was performed on specimens of all patients except J through M.
Myeloma staging is based on the Durie and Salmon staging system with 2 additional parameters: plasma cell labeling index and β-2 microglobulin.
κ and λ stand for kappa and lambda LCs, respectively.
Autologous SCT was performed on 4 patients before their entry into this study.
Only these 2 out of 7 chemotherapy-treated patients showed decreased white cell counts and lymphocyte counts at time of entry to this study.